{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:49:42Z","timestamp":1790707782016,"version":"4.1.0"},"publisher-location":"Cham","reference-count":54,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030602031","type":"print"},{"value":"9783030602048","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-60204-8_14","type":"book-chapter","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:12:58Z","timestamp":1610104378000},"page":"195-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic Efficacy of Plasmalogens for Alzheimer\u2019s Disease, Mild Cognitive Impairment, and Parkinson\u2019s Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Takehiko","family":"Fujino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shamim","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"14_CR1","volume-title":"The state of the art of dementia research: New frontiers","author":"World Alzheimer Report","year":"2018","unstructured":"World Alzheimer Report (2018) The state of the art of dementia research: New frontiers. Alzheimer\u2019s Disease International, London"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/S0140-6736(17)32399-1","volume":"390","author":"RM Anderson","year":"2017","unstructured":"Anderson RM, Hadjichrysanthou C, Evans S, Wong MM (2017) Why do so many clinical trials of therapies for Alzheimer\u2019s disease fail? Lancet 390:2327\u20132329","journal-title":"Lancet"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/107385840100700308","volume":"7","author":"AA Farooqui","year":"2001","unstructured":"Farooqui AA, Horrocks LA (2001) Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7:232\u2013245","journal-title":"Neuroscientist"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JAD-2011-111163","volume":"29","author":"G Lizard","year":"2012","unstructured":"Lizard G, Rouaud O, Demarquoy J, Cherkaoui-Malki M, Iuliano L (2012) Potential roles of peroxisomes in Alzheimer\u2019s disease and in dementia of the Alzheimer\u2019s type. J Alzheimers Dis 29:241\u2013254","journal-title":"J Alzheimers Dis"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.bbadis.2012.05.008","volume":"1822","author":"NE Braverman","year":"2012","unstructured":"Braverman NE, Moser AB (2012) Functions and biosynthesis of plasmalogen lipids in health and disease. Biochim Biophys Acta 1822:1442\u20131452","journal-title":"Biochim Biophys Acta"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/1873-3468.12788","volume":"591","author":"F Dorninger","year":"2017","unstructured":"Dorninger F, Forss-Petter S, Berger J (2017) From peroxisomal disorders to common neurodegenerative diseases - the role of ether phospholipids in the nervous system. FEBS Lett 591:2761\u20132788","journal-title":"FEBS Lett"},{"key":"14_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-1044-1","volume":"18","author":"XQ Su","year":"2019","unstructured":"Su XQ, Wang J, Sinclair AJ (2019) Plasmalogens and Alzheimer\u2019s disease: a review. Lipids Health Dis 18:100","journal-title":"Lipids Health Dis"},{"key":"14_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.plipres.2019.04.003","volume":"74","author":"S Paul","year":"2019","unstructured":"Paul S, Lancaster GI, Meikle PJ (2019) Plasmalogens: a potential therapeutic target for neurodegenerative and cardiometabolic disease. Prog Lipid Res 74:186\u2013195","journal-title":"Prog Lipid Res"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0006-8993(95)00931-F","volume":"698","author":"L Ginsberg","year":"1995","unstructured":"Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer\u2019s disease brain. Brain Res 698:223\u2013226","journal-title":"Brain Res"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/00005072-199907000-00008","volume":"58","author":"Z Guan","year":"1999","unstructured":"Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58:740\u2013747","journal-title":"J Neuropathol Exp Neurol"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1046\/j.1471-4159.2001.00332.x","volume":"77","author":"X Han","year":"2001","unstructured":"Han X, Holtzman DM, McKeel DW Jr (2001) Plasmalogen deficiency in early Alzheimer\u2019s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77:1168\u20131180","journal-title":"J Neurochem"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1194\/jlr.P700023-JLR200","volume":"48","author":"DB Goodenowe","year":"2007","unstructured":"Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW et al (2007) Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer\u2019s disease and dementia. J Lipid Res 48:2485\u20132498","journal-title":"J Lipid Res"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1503\/jpn.090059","volume":"35","author":"PL Wood","year":"2010","unstructured":"Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J et al (2010) Circulating plasmalogen levels and Alzheimer disease assessment scale-cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35:59\u201362","journal-title":"J Psychiatry Neurosci"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000341603","volume":"2","author":"S Oma","year":"2012","unstructured":"Oma S, Mawatari S, Saito K, Fujino T (2012) Changes in phospholipid composition of erythrocyte membrane in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord Extra 2:298\u2013303","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/neu.2015.18","volume":"27","author":"PL Wood","year":"2015","unstructured":"Wood PL, Barnette BL, Kaye JA, Quinn JF, Woltjer RL (2015) Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer\u2019s disease subjects. Acta Neuropsychiatr 27:270\u2013278","journal-title":"Acta Neuropsychiatr"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3233\/JAD-150640","volume":"50","author":"S Yamashita","year":"2015","unstructured":"Yamashita S, Kiko T, Fujiwara H, Hashimoto M, Nakagawa K, Kinoshita M et al (2015) Alterations in the levels of amyloid-\u03b2, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer\u2019s disease: possible interactions between amyloid-\u03b2 and these lipids. J Alzheimers Dis 50:527\u2013553","journal-title":"J Alzheimers Dis"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/1567205014666170505101426","volume":"15","author":"A Zarrouk","year":"2018","unstructured":"Zarrouk A, Debbabi M, Bezine M, Karym EM, Badreddine A, Rouaud O et al (2018) Lipid biomarkers in Alzheimer\u2019s disease. Curr Alzheimer Res 15:303\u2013312","journal-title":"Curr Alzheimer Res"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ab.2007.05.020","volume":"370","author":"S Mawatari","year":"2007","unstructured":"Mawatari S, Okuma Y, Fujino T (2007) Separation of intact plasmalogens and all other phospholipids by a single run of high-performance liquid chromatography. Anal Biochem 370:54\u201359","journal-title":"Anal Biochem"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1271\/bbb.90455","volume":"73","author":"S Mawatari","year":"2009","unstructured":"Mawatari S, Yunoki K, Sugiyama M, Fujino T (2009) Simultaneous preparation of purified plasmalogens and sphingomyelin in human erythrocytes with phospholipase A1 from Aspergillus oryzae. Biosci Biotechnol Biochem 73:2621\u20132625","journal-title":"Biosci Biotechnol Biochem"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1749-6632.2012.06641.x","volume":"1262","author":"T Katafuchi","year":"2012","unstructured":"Katafuchi T, Ifuku M, Mawatari S, Fujino T (2012) Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and \u03b2-amyloid accumulation in adult mice. Ann N Y Acad Sci 1262:85\u201392","journal-title":"Ann N Y Acad Sci"},{"key":"14_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083508","volume":"8","author":"MS Hossain","year":"2013","unstructured":"Hossain MS, Ifuku M, Take S, Kawamura J, Miake K, Katafuchi T (2013) Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. PLoS One 8:e83508","journal-title":"PLoS One"},{"key":"14_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150846","volume":"11","author":"MS Hossain","year":"2016","unstructured":"Hossain MS, Mineno K, Katafuchi T (2016) Neuronal orphan G-protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt signaling. PLoS One 11:e0150846","journal-title":"PLoS One"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ebiom.2017.02.012","volume":"17","author":"T Fujino","year":"2017","unstructured":"Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S et al (2017) Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer\u2019s disease and mild cognitive impairment: a multicenter, randomized, double-blind, placebo-controlled trial. EBioMedicine 17:199\u2013205","journal-title":"EBioMedicine"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4172\/2161-0460.1000419","volume":"8","author":"T Fujino","year":"2018","unstructured":"Fujino T, Yamada T, Asada T, Ichimaru M, Tsuboi Y, Wakana C et al (2018) Effects of plasmalogen on patients with mild cognitive impairment: a randomized, placebo-controlled trial in Japan. J Alzheimers Dis Parkinsonism 8:419","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"14_CR26","first-page":"4","volume":"9","author":"T Fujino","year":"2019","unstructured":"Fujino T, Yamada T, Mawatari S, Shinfuku N, Tsuboi Y, Wakana C et al (2019) Effects of plasmalogen on patients with moderate-to-severe Alzheimer\u2019s disease and blood plasmalogen changes: a multi-center, open-label study. J Alzheimers Dis Parkinsonism 9:4","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"14_CR27","doi-asserted-by":"crossref","unstructured":"Mawatari S, Ohara S, Taniwaki Y, Tsuboi,Y, Maruyama T, Fujino F. Improvement of blood plasmalogens and clinical symptoms in Parkinson\u2019s disease by oral administration of ether phospholipids: a preliminary report. Parkinson\u2019s Disease 2020:2020:671070","DOI":"10.1155\/2020\/2671070"},{"key":"14_CR28","unstructured":"Inamura K, Shinagawa S. Core symptom: cognitive impairment. Nakashima K edited, handbook on dementia.Tokyo: Igaku-Shoin Ltd; 2013. p28\u201335"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00401-011-0836-9","volume":"122","author":"J Kou","year":"2011","unstructured":"Kou J, Kovacs GG, H\u00f6ftberger R, Kulik W, Brodde A, Forss-Petter S et al (2011) Peroxisomal alterations in Alzheimer\u2019s disease. Acta Neuropathol 122:271\u2013283","journal-title":"Acta Neuropathol"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000328929","volume":"1","author":"Y Nakamura","year":"2011","unstructured":"Nakamura Y, Imai Y, Shigeta M, Graf A, Shirahase T, Kim H et al (2011) A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Dis Extra 1:163\u2013179","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"14_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-2187-2-2","volume":"2","author":"DC New","year":"2007","unstructured":"New DC, Wong YH (2007) Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2:2","journal-title":"J Mol Signal"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1021\/bi0156557","volume":"41","author":"LJ Pike","year":"2002","unstructured":"Pike LJ, Han X, Chung KN, Gross RW (2002) Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization\/mass spectrometric analysis. Biochemistry 41:2075\u20132088","journal-title":"Biochemistry"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1677\/jme.0.0320325","volume":"32","author":"B Chini","year":"2004","unstructured":"Chini B, Parenti M (2004) G-protein coupled receptors in lipid rats and caveolae; how, when and why do they go there? J Mol Endocrinol 32:325\u2013338","journal-title":"J Mol Endocrinol"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5056\/jnm15146","volume":"22","author":"SS Yarandi","year":"2016","unstructured":"Yarandi SS, Peterson DA, Treisman GJ, Moran TH, Pasricha PJ (2016) Modulatory effects of gut microbiota on the central nervous system: how gut could play a role in neuropsychiatric health and diseases. J Neurogastroenterol Motil 22:201\u2013212","journal-title":"J Neurogastroenterol Motil"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1476-511X-11-161","volume":"11","author":"S Mawatari","year":"2012","unstructured":"Mawatari S, Katafuchi T, Miake Y, Fujino T (2012) Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats. Lipids Health Dis 11:161\u2013168","journal-title":"Lipids Health Dis"},{"key":"14_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.chemphyslip.2011.06.008","volume":"164","author":"S Wallner","year":"2011","unstructured":"Wallner S, Schmitz G (2011) Plasmalogens the neglected regulatory and scavenging lipid species. Chem Phys Lipids 164:573\u2013589","journal-title":"Chem Phys Lipids"},{"key":"14_CR37","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.2174\/092986709788682164","volume":"16","author":"J Lessig","year":"2009","unstructured":"Lessig J, Fuchs B (2009) Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr Med Chem 16:2021\u20132041","journal-title":"Curr Med Chem"},{"key":"14_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.freeradbiomed.2015.03.012","volume":"84","author":"AM Luoma","year":"2015","unstructured":"Luoma AM, Kuo F, Cakici O, Crowther MN, Denninger AR, Avila RL et al (2015) Plasmalogen phospholipids protect internodal myelin from oxidative damage. Free Radic Biol Med 84:296\u2013310","journal-title":"Free Radic Biol Med"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1196\/annals.1427.023","volume":"1147","author":"C Zhou","year":"2008","unstructured":"Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson\u2019s disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147:93\u2013104","journal-title":"Ann N Y Acad Sci"},{"key":"14_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jns.2004.05.007","volume":"223","author":"M Sohmiya","year":"2004","unstructured":"Sohmiya M, Tanaka M, Tak NW, Yanagisawa M, Tanino Y, Suzuki Y et al (2004) Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson\u2019s disease. J Neurol Sci 223:161\u2013166","journal-title":"J Neurol Sci"},{"key":"14_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1515\/CCLM.2009.205","volume":"47","author":"C Dragonas","year":"2009","unstructured":"Dragonas C, Bertsch T, Sieber CC, Brosche T (2009) Plasmalogens as a marker of elevated systemic oxidative stress in Parkinson\u2019s disease. Clin Chem Lab Med 47:894\u2013897","journal-title":"Clin Chem Lab Med"},{"key":"14_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:19","journal-title":"Transl Neurodegener"},{"key":"14_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2015.12.013","volume":"613","author":"M Moraitou","year":"2016","unstructured":"Moraitou M, Dermentzaki G, Dimitriou E, Monopolis I, Dekker N, Aerts H et al (2016) \u03b1-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress. Neurosci Lett 613:1\u20135","journal-title":"Neurosci Lett"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbr.2015.03.012","volume":"286","author":"L Gregoire","year":"2015","unstructured":"Gregoire L, Smith T, Senanayake V, Mochizuki A, Miville-Godbout E, Goodenowe D et al (2015) Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 286:328\u2013337","journal-title":"Behav Brain Res"},{"key":"14_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151020","volume":"11","author":"E Miville-Godbout","year":"2016","unstructured":"Miville-Godbout E, Bourque M, Morissette M, Al-Sweidi S, Smith T, Mochizuki A et al (2016) Plasmalogen augmentation reverses striatal dopamine loss in MPTP mice. PLoS One 11:e0151020","journal-title":"PLoS One"},{"key":"14_CR46","doi-asserted-by":"crossref","unstructured":"Snowdon D (1997)\u00a0Aging and Alzheimer\u2019s disease: lessons from the Nun Study. Gerontologist 37:150\u2013156","DOI":"10.1093\/geront\/37.2.150"},{"key":"14_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M et al (2018) Trial of Solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med 378:321\u2013330","journal-title":"N Engl J Med"},{"key":"14_CR48","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B et al (2018) Randomized trial of Verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 378:1691\u20131703","journal-title":"N Engl J Med"},{"key":"14_CR49","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.1073\/pnas.1917461117","volume":"117","author":"ER Werner","year":"2020","unstructured":"Werner ER, Keller MA, Sailer S, Lackner K, Koch J, Hermann M et al (2020) The TMEM189 gene encodes plasmanylethanolamine desaturase which introduces the characteristic vinyl ether double bond into plasmalogens. PNAS 117:7792\u20137798","journal-title":"PNAS"},{"key":"14_CR50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jnc.14224","volume":"143","author":"J Walter","year":"2017","unstructured":"Walter J, Kemmerling N, Wunderlich P, Glebov K (2017) \u03b3-Secretase in microglia - implications for neurodegeneration and neuroinflammation. J Neurochem 143:445\u2013454","journal-title":"J Neurochem"},{"key":"14_CR51","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.3390\/ijms20163929","volume":"20","author":"F Dorninger","year":"2019","unstructured":"Dorninger F, Gundacker A, Zeitler G, Pollak DD, Berger J (2019) Ether lipid deficiency in mice produces a complex behavioral phenotype mimicking aspects of human psychiatric disorders. Int J Mol Sci 20:3929","journal-title":"Int J Mol Sci"},{"key":"14_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.schres.2014.11.032","volume":"161","author":"PL Wood","year":"2015","unstructured":"Wood PL, Unfried G, Whitehead W, Phillipps A, Wood JA (2015) Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia. Schizophr Res 161:506\u2013510","journal-title":"Schizophr Res"},{"key":"14_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.psychres.2012.02.019","volume":"198","author":"R Kaddurah-Daouk","year":"2012","unstructured":"Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, Yao JK, Nimgaonkar VL et al (2012) Impaired plasmalogens in patients with schizophrenia. Psychiatry Res 198:347\u2013352","journal-title":"Psychiatry Res"},{"key":"14_CR54","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JAD-171036","volume":"62","author":"F Dorninger","year":"2018","unstructured":"Dorninger F, Moser AB, Kou J, Wiesinger C, Forss-Petter S, Gleiss A et al (2018) Alterations in the plasma levels of specific choline phospholipids in Alzheimer\u2019s disease mimic accelerated aging. J Alzheimers Dis 62:841\u2013854","journal-title":"J Alzheimers Dis"}],"container-title":["Advances in Experimental Medicine and Biology","Peroxisome Biology: Experimental Models, Peroxisomal Disorders and Neurological Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-60204-8_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T12:36:49Z","timestamp":1610109409000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-60204-8_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030602031","9783030602048"],"references-count":54,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-60204-8_14","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"9 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}